Citations

Clear

167 citation(s) found for "Grogan, M".

Mutation‐specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas
Smyrk, Thomas C. , Tougeron, David , Thibodeau, Stephen N. , Singh, Shalini , Murányi, Andrea , Shanmugam, Kandavel , Grogan, Thomas M. , Shi, Qian , Sinicrope, Frank A. , Alberts, Steven R. , Shi, Qian , Tougeron, David

Mayo Clinic

Cancer | May 8, 2013 | Volume: 119 | Issue: 15 | Pages: 2765-2770

10.1002/cncr.28133 | PMID 23657789 Get It

BACKGROUNDA point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti‐EGFR antibody therapy in patients with colorectal carcinoma. BRAFV600E mutations are frequently detected in tumors with microsatellite instability and indicate a sporadic origin. We used a mutation‐specific antibody to examine mutant BRAFV600E protein expression and its concordance with BRAFV600E mutation data.METHODSPrimary stage III colon carcinomas were analyzed for BRAFV600E mutations in exon 15, and 50 BRAFV600E mutation carriers and 25 wild‐type tumors were selected for analysis of BRAF proteins by immunohistochemistry (IHC). IHC was performed in archival tissue specimens using a pan‐BRAF antibody and a mutation‐specific antibody against BRAFV600E proteins. Staining was scored by 2 pathologists who were blinded to clinical and mutation data.RESULTSUsing a pan‐BRAF antibody, total BRAF protein expression was observed in the tumor cell cytoplasm in 74 of 75 colon carcinomas. A mutation‐specific antibody identified diffuse cytoplasmic staining of mutant BRAFV600E proteins in 49 of 74 cancers. Analysis using a polymerase chain reaction‐based assay revealed that all 49 of these cancers carried BRAFV600E mutations. In contrast, BRAFV600E staining was absent in all 25 tumors that carried wild‐type copies of BRAF.CONCLUSIONSA BRAF mutation‐specific (V600E) antibody detected tumors with BRAFV600E mutations and exhibited complete concordance with a DNA‐based method. These results support the use of IHC as a simplified strategy to screen colorectal cancers for BRAFV600E mutations in clinical practice. Cancer 2013;119:2765–2770. © 2013 American Cancer Society.
Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis
Lin, Grace , Dispenzieri, Angela , Kyle, Robert A. , Grogan, Martha , Brady, Peter A. , Dispenzieri, Angela

Mayo Clinic

Journal of Cardiovascular Electrophysiology | February 22, 2013 | Volume: 24 | Issue: 7 | Pages: 793-798

10.1111/jce.12123 | PMID 23489983 Get It

ICD in Cardiac AmyloidosisBackgroundCardiac amyloidosis (CA) is associated with increased risk of sudden cardiac arrest. Although ICD therapy improves survival in patients with cardiomyopathy due to other etiologies, the benefit of ICD therapy in patients with CA is unclear in large part due to limited data on the precise mechanism of sudden cardiac arrest and selection of patients with cardiac amyloidosis for ICD therapy.ObjectiveThe objective was to determine the benefit of ICD therapy in cardiac amyloidosis.MethodsWe reviewed all ICD implant indications, procedures, and therapies, of CA patients evaluated at Mayo Clinic between 2000 and 2009.ResultsA total of 53 patients with CA (33 AL, 10 senile, 9 familial, and 1 AA) who underwent ICD implantation were included. Indication for ICD implantation was for primary prevention of sudden cardiac arrest in 41 (77%) patients and secondary prevention in 12 (23%) patients. The rate of appropriate ICD shocks was 32% in the first year and was observed almost exclusively in AL amyloidosis patients, occurring in 15 patients (12 AL amyloidosis, 2 senile, 1 AA). Appropriate ICD shocks were more frequent in patients with prior sudden cardiac arrest or sustained ventricular arrhythmias (secondary prevention indication), and less frequent in patients who presented with decreased ejection fraction or syncope.ConclusionsA high rate of appropriate ICD shocks was observed especially in patients with AL‐type amyloidosis. However, appropriate ICD therapy did not translate into overall survival benefit, suggesting that selection of patients with CA who might be candidates for ICD is imprecise.
Headache Direction and Aura Predict Migraine Responsiveness to Rimabotulinumtoxin B
Grogan, Patrick, Alvarez, Maria Victoria, Jones, Lyell K. , Jones, Lyell K

Mayo Clinic

Headache: The Journal of Head and Face Pain | November 5, 2012 | Volume: 53 | Issue: 1 | Pages: 126-136

10.1111/j.1526-4610.2012.02288.x | PMID 23126597 Get It

Objective To report a retrospective analysis of patients with migraine headaches treated with rimabotulinumtoxin B as preventive treatment, investigating an association between clinical responsiveness with migraine directionality and migrainous aura. Background The P hase III R esearch E valuating M igraine P rophylaxis T herapy studies demonstrated onabotulinumtoxin A is effective in the preventive management of chronic migraine headaches. J akubowski et al reported greater response to onabotulinumtoxin A in migraine patients reporting inward‐directed head pain (imploding or ocular) compared with outward‐directed head pain (exploding), suggesting subpopulations of patients may be better candidates for its use. No correlation was found between those reporting migrainous aura and onabotulinumtoxin A responsiveness. Methods One hundred twenty‐eight migraine patients were identified who had received rimabotulinumtoxin B injections over an average of 22 months, or 7 injection cycles. Migraine directionality was reported as inward directed (imploding, n = 72), eye centered (ocular, n = 28), outward directed (exploding, n = 16), and mixed (n = 12). Results One hundred two out of one hundred twenty‐eight patients (80%) improved; of these, 58 (57%) demonstrated a >75% reduction in monthly headache frequency (“>75%‐responders”), 76% of which noted sustained benefits >12 months with repeated injections every 10‐12 weeks. Those reporting ocular‐ and imploding‐directed headaches were significantly more likely to be >75%‐responders, compared with exploding‐ and mixed‐directed headaches ( P < .0025). Patients with ocular‐directed headaches were most likely to be sustained >75%‐responders. Patients reporting migrainous aura were more likely to be >75%‐responders ( P = .0007). Those reporting exploding‐ and mixed‐directed headaches were more likely to be nonresponders ( P < .0001). Conclusions Reported migraine directionality and presence of migrainous aura predict migraine headache responsiveness to rimabotulinumtoxin B injections.
Surgical Repair of Tetralogy of Fallot at Age 83
Hussain, Fareeda Taher Nazer, Grogan, Martha , Dearani, Joseph A.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | October 25, 2012 | Volume: 3 | Issue: 4 | Pages: 518-520

10.1177/2150135112451031 | PMID 23804918 Get It

Tetralogy of Fallot (TOF) is a cyanotic congenital heart defect typically diagnosed in infancy and treated with early surgical correction. We report a patient with TOF diagnosed at age 78. Successful surgical repair was performed at age 83, the oldest reported age of surgical correction of this condition. Despite a complicated surgical and postoperative course, the patient is doing well almost four years later.
Improvement in Myocardial Delayed Enhancement After Autologous Stem Cell Transplant in a Patient With Light Chain Amyloidosis
Bonnichsen, Crystal R. , Glockner, James F., Grogan, Martha

Mayo Clinic

Circulation: Heart Failure | May 15, 2012 | Volume: 5 | Issue: 3 | Pages: No page available

10.1161/circheartfailure.112.967935 | PMID 22589368 Get It

Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules
Pecot, Chad V. , Li, Ming , Zhang, Xueqiong J., Rajanbabu, Rama, Calitri, Ciara, Bungum, Aaron O., Jett, James R., Putnam, Joe B. , Callaway‐Lane, Carol , Deppen, Steve, Grogan, Eric L. , Worrell, John A., Shyr, Yu , Massion, Pierre P. , Carbone, David Paul , Moons, Karel G.M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 7, 2012 | Volume: 21 | Issue: 5 | Pages: 786-792

10.1158/1055-9965.epi-11-0932 | PMID 22374995 Get It

Abstract Background: Current management of lung nodules is complicated by nontherapeutic resections and missed chances for cure. We hypothesized that a serum proteomic signature may add diagnostic information beyond that provided by combined clinical and radiographic data. Methods: Cohort A included 265 and cohort B 114 patients. Using multivariable logistic regression analysis we calculated the area under the receiver operating characteristic curve (AUC) and quantified the added value of a previously described serum proteomic signature beyond clinical and radiographic risk factors for predicting lung cancer using the integration discrimination improvement (IDI) index. Results: The average computed tomography (CT) measured nodule size in cohorts A and B was 37.83 versus 23.15 mm among patients with lung cancer and 15.82 versus 17.18 mm among those without, respectively. In cohort A, the AUC increased from 0.68 to 0.86 after adding chest CT imaging variables to the clinical results, but the proteomic signature did not provide meaningful added value. In contrast, in cohort B, the AUC improved from 0.46 with clinical data alone to 0.61 when combined with chest CT imaging data and to 0.69 after adding the proteomic signature (IDI of 20% P = 0.0003). In addition, in a subgroup of 100 nodules between 5 and 20 mm in diameter, the proteomic signature added value with an IDI of 15% (P ≤ 0.0001). Conclusions: The results show that this serum proteomic biomarker signature may add value to the clinical and chest CT evaluation of indeterminate lung nodules. Impact: This study suggests a possible role of a blood biomarker in the evaluation of indeterminate lung nodules. Cancer Epidemiol Biomarkers Prev; 21(5); 786–92. ©2012 AACR.
Premature Ventricular Contraction-Induced Cardiomyopathy
Cha, Yong‐Mei , Lee, Glenn K., Klarich, Kyle W. , Grogan, Martha

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | February 14, 2012 | Volume: 5 | Issue: 1 | Pages: 229-236

10.1161/circep.111.963348 | PMID 22334430 Get It

High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement
Madan, Sumit , Kumar, Shaji , Dispenzieri, Angela , Lacy, Martha Q. , Hayman, Suzanne R. , Dingli, David , Rajkumar, S. Vincent , Leung, Nelson , Grogan, Martha , Buadi, Francis K. , Hogan, William J. , Gertz, Morie A. , Rajkumar, S Vincent , Leung, Nelson , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | December 7, 2011 | Volume: 119 | Issue: 5 | Pages: 1117-1122

10.1182/blood-2011-07-370031 | PMID 22147893 Get It

Abstract High-dose melphalan (HDM) plus stem cell transplantation is an effective treatment for light-chain amyloidosis (AL), but is associated with high treatment-related mortality in patients with cardiac involvement. We studied 187 patients with cardiac involvement with AL who underwent HDM between 1996 and 2008. The median age was 57 years and the median time from diagnosis to HDM was 3.6 months. Half of the patients received reduced-dose melphalan (100-160 mg/m2). The median overall survival (OS) was 66 months, 54 months from diagnosis and HDM, respectively, and 91 patients (49%) were alive at the last follow-up 52 months (median) from HDM. Thirty patients (16%) died within 100 days of transplantation; only low serum albumin predicted early deaths. Overall, hematologic response (HR) and cardiac responses were seen in 66% and 41% of patients, respectively. The median OS for patients with and without HR was not reached and 22 months, respectively (P < .01); and for those with any decrease and no decrease in N-terminal-pro-brain natriuretic peptide was not reached and 26 months, respectively (P < .01). In multivariate analysis of baseline factors, only reduced-dose melphalan predicted shorter OS. HDM is feasible in patients with cardiac amyloidosis, and achievement of HR and organ response is associated with improved survival.
Oxygen Is a Master Regulator of the Immunogenicity of Primary Human Glioma Cells
Olin, Michael R. , Andersen, Brian M. , Litterman, Adam J. , Grogan, Patrick T., Sarver, Aaron L. , Robertson, Paul T., Liang, Xueqing , Parney, Ian F. , Hunt, Matthew A. , Ohlfest, John R., Chen, Wei , Blazar, Bruce R. , Parney, Ian F

Mayo Clinic

Cancer Research | September 10, 2011 | Volume: 71 | Issue: 21 | Pages: 6583-6589

10.1158/0008-5472.can-11-1166 | PMID 21908554 Get It

Abstract With recent approval of the first dendritic cell (DC) vaccine for patient use, many other DC vaccine approaches are now being tested in clinical trials. Many of these DC vaccines employ tumor cell lysates (TL) generated from cells cultured in atmospheric oxygen (∼20% O2) that greatly exceeds levels found in tumors in situ. In this study, we tested the hypothesis that TLs generated from tumor cells cultured under physiologic oxygen (∼5% O2) would be more effective as a source for DC antigens. Gene expression patterns in primary glioma cultures established at 5% O2 more closely paralleled patient tumors in situ and known immunogenic antigens were more highly expressed. DCs treated with TLs generated from primary tumor cells maintained in 5% O2 took up and presented antigens to CD8 T cells more efficiently. Moreover, CD8 T cells primed in this manner exhibited superior tumoricidal activity against target cells cultured in either atmospheric 20% O2 or physiologic 5% O2. Together, these results establish a simple method to greatly improve the effectiveness of DC vaccines in stimulating the production of tumoricidal T cells, with broad implications for many of the DC-based cancer vaccines being developed for clinical application. Cancer Res; 71(21); 6583–9. ©2011 AACR.
Abstract 5375: Effective temozolomide sensitization by the ATM inhibitor KU 55933 is lost with the emergence of TMZ resistance in glioblastoma cell lines
Nadkarni, Aditi , Schwingler, Paul M., Grogan, Patrick T., Mladek, Ann C. , Sarkaria, Jann N.

Mayo Clinic

Cancer Research | February 25, 2011 | Volume: 70 | Issue: 8_Supplement | Pages: 5375-5375

10.1158/1538-7445.am10-5375 Get It

Abstract Cellular DNA repair mechanisms limit the success of temozolomide (TMZ) therapy in the treatment of glioblastoma (GBM) by countering TMZ induced DNA damage and contributing towards TMZ resistance. Hence DNA repair inhibition has the potential to overcome TMZ resistance in GBM. KU-55933 is a small molecule inhibitor of Ataxia telangiectasia (A-T) mutated protein (ATM), which plays a critical role in DNA repair. In this study, the chemosensitizing effects of KU-55933 were studied in combination with TMZ in two glioblastoma cell lines, U251 and U87. Treatment with a combination of TMZ and KU-55933, compared to TMZ alone, resulted in a significant increase in cell killing [U251 survival: 0.004 ± 0.0015 vs. 0.08 ± 0.01 (p&lt;0.001), respectively, and U87 survival: 0.02 ± 0.005 vs. 0.04 ± 0.002 (p&lt;0.001), respectively]. To evaluate whether KU-55933 would enhance the efficacy of TMZ in resistant lines, the U251TMZ and U87TMZ lines were generated by subjecting U251 and U87 cells to in vitro TMZ selection. Interestingly, in these TMZ resistant lines, a combination of TMZ and KU-55933 did not result in a significant increase in cell killing compared to treatment with TMZ alone [U251TMZ survival: 0.84 ± 0.03 vs. 0.87 ± 0.01 (p&gt;0.1), respectively, and U87TMZ survival: 0.62 ± 0.03 vs 0.63 ± 0.09 (p&gt;0.1), respectively]. To investigate the potential mechanism of resistance to TMZ sensitization by KU-55933, the effect of KU-55933 on TMZ induced G2 arrest was analyzed by flow cytometry. Consistent with the clonogenic survival data, a combination of TMZ and KU-55933 significantly increased the number of cells arrested in the G2 phase in both parental lines, compared to treatment with TMZ alone [U251 G2 fraction: 61.8 ± 1.1% vs. 35 ± 0.8% (p&lt;0.001), respectively, and U87 G2 fraction 25 ± 0.2% vs.18.6 ± 0.4% (p&lt;0.001), respectively]. Co-treatment of the TMZ resistant lines with KU-55933 and TMZ also increased the fraction of cells arrested G2, as compared to treatment with TMZ alone, although the extent of the G2 arrest was markedly attenuated relative to the parental cells [U251TMZ G2 fraction: 20 ± 0.6% vs. 12 ± 0.4% (p&lt;0.001), respectively, and U87TMZ G2 fraction 14 ± 3.14% vs. 9 ± 0.5%, (p&gt;0.1), respectively]. Preliminary evaluation of double stranded break (DSB) repair by immunofluorescent monitoring of γH2AX foci formation 72 hours after treatment demonstrated a 2-fold increase in the number of unrepaired DSBs in U251 cells treated with a combination of TMZ and KU-55933, as compared to TMZ alone, (p&lt;0.001) while no increase in foci formation was observed in the U251TMZ cells treated with combined therapy as compared to TMZ alone (p&gt;0.1). In conclusion, KU-55933 sensitizes only inherently TMZ sensitive lines to TMZ and these effects may be linked to inhibition of ATM-mediated DNA damage repair following TMZ treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 5375.